Johnson & Johnson sued the U.S. Health and Human Services Department on Tuesday, accusing the agency of blocking its plan to ...

Johnson & Johnson is challenging a federal health agency for blocking its plan to discount drugs through a rebate model ...

now the second-largest federal drug initiative after Medicare, has been exploited by entities not intended initially as beneficiaries, sidelining patients. In August 2024, Johnson & Johnson proposed a ...

SEOUL, Nov. 13 (Yonhap) -- The antitrust regulator said Wednesday it has imposed fines worth 300 million won (US$213,000) on ...

Johnson & Johnson files suit against HHS over 340B program, proposing hospitals pay full price upfront for drugs and receive ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

J&J announced its plan to replace upfront 34B discounts with the rebate plan in August, but HRSA told the company on Sept. 27 that it would initiate proceedings to terminate the drug maker's ...

Over time, biosimilars are gaining traction in the US and becoming preferred products, explained James D. Chambers, PhD, of ...

The lawsuit escalates the pharmaceutical industry’s fight to rein in the federal drug-discount program known as 340B ... and ...

Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, ...

ORANGE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- via IBN – Astiva Health, a fast-growing leader in culturally responsive ...

Trump's designations for foreign policy and border positions have sent signals to Canada, and the rest of the world, about ...